Latest California Healthline Stories
Mood-Altering Mushroom Sales Bloom Despite Safety Concerns
The well-known “Amanita muscaria” mushroom is legal to possess and consume in 49 states. The market for gummies, powders, and capsules containing extracts of the fungus is raising eyebrows, though, amid concerns from the FDA and in the absence of human clinical trials.
Watch: 5th Circuit Judges Question Two-Decade-Old Approval of Abortion Pill
The 5th Circuit Court of Appeals in New Orleans heard oral arguments Wednesday in a case brought by conservative Christian abortion opponents seeking to revoke FDA approval of mifepristone, a medication used in more than half of abortions in the U.S.
KFF Health News' 'What the Health?': The Crisis Is Officially Ending, but Covid Confusion Lives On
The public health emergency declaration for covid-19 ends May 11, ushering in major changes in how Americans can access and pay for the vaccines, treatments, and tests particular to the culprit coronavirus. But not everyone will experience the same changes, creating a confusing patchwork of coverage — not unlike health coverage for other diseases. Meanwhile, outside advisers to the FDA formally recommended allowing a birth control pill to be sold without a prescription. If the FDA follows the recommendation, it would represent the first over-the-counter form of hormonal contraception. Margot Sanger-Katz of The New York Times, Tami Luhby of CNN, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KFF Health News’ Julie Rovner to discuss these issues and more. Plus for “extra credit” the panelists suggest health policy stories they read this week they think you should read, too.
Marihuana legal es más potente que nunca pero no está bien regulada
Cientos de miles de personas llegan a salas de emergencias por crisis relacionadas con la marihuana, y millones sufren trastornos psicológicos vinculados al consumo de cannabis, según investigaciones federales.
Legal Pot Is More Potent Than Ever — And Still Largely Unregulated
As marijuana has become far more mainstream, potent, and sometimes dangerous, uneven regulation at the state and federal levels leaves consumers at risk.
Federal Rules Don’t Require Period Product Ingredients on Packaging Labels. States Are Stepping In.
New York and California have passed laws requiring disclosure of ingredients on menstrual product packaging. Advocates want more transparency across the U.S.
Listen: Mifepristone Remains Available for Now. What Happens Next?
The Supreme Court on April 21 ruled that the abortion pill mifepristone should remain widely available while the lower courts consider the issue, blocking earlier rulings that banned or restricted access to the drug. KFF Health News’ Julie Rovner joined NPR’s “Weekend All Things Considered” to discuss the complicated case.
Social Media Is Fueling Enthusiasm for New Weight Loss Drugs. Are Regulators Watching?
Online platforms are overflowing with testimonials for GLP-1s. The drugs show promise for inducing weight loss, but many aren’t FDA-approved for that use.
Redes sociales alimentan obsesión por las drogas para bajar de peso, sin hablar de riesgos
La competencia para hacerse con un mercado que podría valer $100.000 millones al año, solo para los fabricantes de medicamentos, ha desencadenado una ola de publicidad que preocupa a las autoridades sanitarias y médicos de todo el mundo.
KFF Health News' 'What the Health?': The Confusing Fate of the Abortion Pill
The legality and availability of the abortion pill mifepristone is in question after a federal judge in Texas canceled the FDA’s approval of the first drug used in the two-drug medication abortion regimen. A 5th Circuit Court of Appeals panel overruled that decision in part, saying the pill should remain available, but only under the onerous restrictions in place before 2016. Meanwhile, another federal judge in Washington state issued a ruling in a separate case that conflicts with the Texas decision, ordering the FDA not to roll back any of its restrictions on the drug. Victoria Knight of Axios, Shefali Luthra of The 19th, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more.